Polimorfismos de nucleotídeos único no gene IGFBP3 e o processo de carcinogênese: uma revisão sistemática

Paulo Pedro De Freitas,Denise Macedo Da Silva,Cristiane Araújo Nascimento,Edilson Leite De Moura,Ana Caroline Melo Dos Santos,Karol Fireman De Farias,Aline Cristine Pereira E Silva,Elaine Virgínia Martins De Souza Figueiredo,Israel Faustino Dos Santos

doi:10.33448/rsd-v10i1.11978

Abstract

Introduction: Insulin-like growth factor binding protein -3 (IGFBP3) is the main mediator of IGF-1/IGF-1R binding, and may inhibit the binding between IGF-1 and IGF-1R and trigger cell growth suppression. Method: This study is a systematic review in which searches were conducted in Pubmed, Web of science, Science direct and Scopus databases for studies published in the period 2010-2020, including case-control studies that evaluated the association of polymorphisms in the IGFBP3 gene with cancer. Results: Of the 6 studies included, 5 were conducted in China and 1 in Iran, published in 2015 (n=2), 2014 (n=2), 2013 (n=1) and 2011 (n=1). In all, there were 5 types of cancer studied: esophagus (n=2), prostate (n=1), colorectal (n=1), breast (n=1) and gastric (n=1). In the studies chosen, 8 SNPs located in the IGFBP3 gene were evaluated: rs2854744, rs2854746, rs2132572, rs9282734, rs3110697, rs2960436, rs2270628 and rs10282088. Only the Zhao et al studies. (2015) and Liu et al. (2015) found a relationship between SNPs in the IGFBP3 gene with cancer. Two studies (Qian et al., 2014 and Qian et al., 2011) did not describe allelic frequencies in their results. Conclusion: Based on the studies we can demonstrate that the findings on the association of polymorphisms in the IGFBP3 gene with cancers are confusing, divergent and the role of the IGF pathway in carcinogenesis has not been clearly defined. However, the studies bring strong evidence that suggests possible relationships of this pathway and genetic variants with the carcinogenesis process in several types of cancer.

Highlights

Insulin-like growth factor binding protein -3 (IGFBP3) is the main mediator of IGF-1/IGF-1R binding, and may inhibit the binding between IGF-1 and IGF-1R and trigger cell growth suppression
The following research question: "single nucleotide polymorphisms in the IGFBP3 gene are involved in the carcinogenesis process?", was elaborated based on acronical of PICOS with Population (P): cancer patients; Intervention (I): presence of single nucleotide polymorphisms in the IGFBP3 gene; Comparator (C): healthy patients; Outcome (O): risk assessment or protection of SNPs in the IGFBP3 gene in relation to carcinogenesis; Study design (S): case-control; Additional results: identify the most polymorphism-related types of cancer in the IGBP3 gene
We can demonstrate that the findings on the association of polymorphisms in the IGFBP3 gene with cancers are confusing, divergent and the role of the IGF pathway in carcinogenesis has not been clearly defined

Summary

Introduction

Insulin-like growth factor binding protein -3 (IGFBP3) is the main mediator of IGF-1/IGF-1R binding, and may inhibit the binding between IGF-1 and IGF-1R and trigger cell growth suppression. This protein, together with the other IFGs, are involved in cancer signaling networks, acting in suppression, cell proliferation, induction to programmed cell death and playing roles in normal and/or malignant cell growth processes. These characteristics demonstrate that the IGF signaling pathway is related to the development of cancer (Tang et al, 2019; Wang et al, 2018; Chen et al, 2018)

Methods

Results

Conclusion